Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1133-1145

  Minier, Tünde ^a   Nagy, Zoltán ^b   Bálint, Zsófia ^a   Farkas, Helka ^a   Radics, Judit ^a   Kumánovics, Gábor ^a   Czömpöly, Tamás ^a   Simon, Diána ^a   Varjú, Cecília ^a   Németh, Péter ^a   Czirják, László ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Department of Internal Medicine   (Hungary)

Author keywords

Biomarkers; Categorical principal component analysis; Disease activity; Scleroderma; Self assessment questionnaire; Skin ulcers; Systemic sclerosis; Systemic sclerosis activity index

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBON MONOXIDE; P SELECTIN GLYCOPROTEIN LIGAND 1; VASCULOTROPIN;

ADULT; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX; FEMALE; FORCED VITAL CAPACITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; JOINT CONTRACTURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SELF EVALUATION; SKIN ULCER; SPIROMETRY; SYSTEMIC SCLEROSIS;

ADULT; AGED; BIOLOGICAL MARKERS; DISABILITY EVALUATION; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; OBSERVER VARIATION; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN ULCER; STATISTICS AS TOPIC;

EID: 77953484773     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq022     Document Type: Article

References (50)

1. Della Rossa A, Valentini G, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60: 585-91.
2. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
3. Valentini G, Bencivelli W, Bombardieri S et al. European scleroderma study group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
4. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European scleroderma study group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
5. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21:S39-41.
6. Doran JP, Veale DJ. Biomarkers in systemic sclerosis. Rheumatology 2008;47(SUPPL. 5):v36-8.
7. Greaves M, Malia RG, Milford Ward A et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br J Rheumatol 1988;27:281-5.
8. Matucci-Cerinic M, Pignone A, Iannone F et al. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 1990;84:283-7.
9. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
10. Yanaba K, Takehara K, Sato S. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis. Ann Rheum Dis 2004;63: 583-7.
11. Distler O, Distler JH, Scheid A et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95: 109-16.
12. Denton CP, Merkel PA, Furst DE et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
13. Allanore Y, Borderie D, Lemarechal H, Cherruau B, Ekindjian OG, Kahan A. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 2003;30:68-73.
14. Nagy Z, Czirjak L. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 2005;23:165-72.
15. Alekperov RT, Baranov AA, Abaitova NE. Associacii urovna C-reaktivnogo belka s kliniceskimi proavleniami pri sistemnoi sklerodermii [Clinical associations of C-reactive protein in systemic sclerosis]. Ter Arkh 2006;78:30-5.
16. Czirjak L, Kumanovics G, Varju C et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
17. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003;21:429-36.
18. Asano Y, Ihn H, Yamane K et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001;44:1363-9.
19. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000;200:196-201.
20. Kumanovics G, Minier T, Radics J, Palinkas L, Berki T, Czirjak L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008;26:414-20.
21. Maeda M, Ichiki Y, Aoyama Y, Kitajima Y. Surfactant protein D (SP-D) and systemic scleroderma (SSc). J Dermatol 2001;28:467-74.
22. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201.
23. Matsushita T, Fujimoto M, Hasegawa M et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007;34:2056-62.
24. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 2004; 31:514-9.
25. Allanore Y, Borderie D, Meune C et al. Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005; 64:481-3.
26. Hanke K, Dahnrich C, Bruckner CS et al. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009;11:R28.
27. Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003;48:1363-73.
28. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
29. Komocsi A, Pinter T, Faludi R et al. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2010;69:202-5.
30. Furst DE. Measuring outcomes in PAH: the gap between the measures that are used and their validity. Ann N Y Acad Sci 2007;1107:410-6.
31. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
32. Czirjak L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66: 966-9.
33. Nagy Z, Balint Z, Farkas H et al. Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis. Rheumatology 2009;48:309-14.
34. Nagy Z, Bálint Z, Farkas H et al. A szisztémás sclerosisos betegek számára készült módosított HAQ kérdo{double acute}ív hazai adaptációja és validálása [The adaptation and validation of scleroderma Health Assessment Questionnaire for the Hungarian systemic sclerosis patients]. Magyar Reumatológia 2007;48:208-18.
35. Medsger TA Jr. Assessment of damage and activity in systemic sclerosis. Curr Opin Rheumatol 2000;12:545-8.
36. Roberts-Thomson AJ, Massy-Westropp N, Smith MD, Ahern MJ, Highton J, Roberts-Thomson PJ. The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis. Rheumatol Int 2006;26: 439-44.
37. Funauchi M, Shimadsu H, Tamaki C et al. Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis. J Rheumatol 2006;33:903-6.
38. Linting M, Meulman JJ, Groenen PJ, van der Koojj AJ. Nonlinear principal components analysis: introduction and application. Psychol Methods 2007;12:336-58.
39. Gazi H, Pope JE, Clements P et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007;34:501-9.
40. Khanna D, Furst DE, Hays RD et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65: 1325-9.
41. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48: 516-22.
42. Diaconu D, Fransen J, Vonk MC et al. Disease activity criteria for patients with early systemic sclerosis. Ann Rheum Dis 2009;68:275.
43. Hanitsch LG, Burmester GR, Witt C et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations-an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) register. Rheumatology 2009;48:70-3.
44. Hudson M, Steele R, Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93-8.
45. Della Rossa A, Bombardieri S, Valentini G. Comment on: disease activity criteria in scleroderma. Semin Arthritis Rheum 2008;37:271-2.
46. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004;31:1112-20.
47. Kahaleh MB, Osborn I, LeRoy EC. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med 1981;94:482-4.
48. Lau CS, McLaren M, Belch JJ. Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. Br J Rheumatol 1991;30:433-6.
49. Scheja A, Akesson A, Geborek P et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 2001;3: 178-82.
50. Choi JJ, Min DJ, Cho ML et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003;30:1529-33.